Association Between Regular Aspirin Use and Circulating Markers of Inflammation: A study within the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial
Menée sur 1 819 participants inclus dans un essai de dépistage du cancer de la prostate, du poumon, du côlon-rectum ou de l'ovaire (âge : 55 à 74 ans), cette étude évalue l'association entre l'utilisation régulière d'aspirine et le niveau sérique de 78 marqueurs de l'inflammation
Background : Regular aspirin use may decrease cancer risk by reducing chronic inflammation. However, associations between aspirin use and circulating markers of inflammation have not been well-studied. Methods : Serum levels of 78 inflammatory markers were measured in 1,819 55-74 year-old men and women in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Data were combined from 3 completed case-control studies and re-weighted to the PLCO screening arm. Self-reported aspirin and ibuprofen use (number of tablets taken per day/week/month) over the previous 12 months was collected at baseline. Associations between i) non-regular (<4 tablets/month), ii) low (1-4 tablets/week), iii) moderate (1 tablet/day) or iv) high (2+ tablets/day) regular aspirin or ibuprofen use and marker levels were assessed with weighted logistic regression. Results : Aspirin use was nominally associated with (ptrend across categories≤0.05) decreased levels of chemokine C-C motif ligand 15 (CCL15) (OR 0.5; 95%CI: 0.3-0.8; moderate versus non-regular use); soluble vascular endothelial growth factor receptor 2 (sVEGFR2) (OR 0.7; 95%CI: 0.4-1.0); soluble tumor necrosis factor receptor 1 (sTNFR1) (OR 0.6; 95%CI: 0.4-0.9) and increased levels of CCL13 (OR 1.3; 95%CI: 0.8-2.1); CCL17 (OR 1.1; 95%CI: 0.7-1.9) and interleukin 4 (IL-4) (OR 1.6; 95%CI: 0.9-2.8). Trends were not statistically significant following correction for multiple comparisons. Likewise, no statistically significant associations were observed between ibuprofen use and marker levels. Conclusions : No significant associations were observed between regular aspirin use and the inflammatory markers assessed. Impact : Additional studies are needed to better understand the relationship between aspirin use, chronic inflammation and cancer risk.